Therapeutic trials for subjective cognitive impairment to prevent Alzheimer's disease are feasible and necessary.
Studies of therapeutic agents in SCI treatment and resultant Alzheimer's disease prevention appear to be feasible. These trials are also necessary from a public health perspective.
Reisberg et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: